Physician
Endocrinology
Dr. Ralph A. Defronzo, MD
|
|
Give Review
Ralph A. Defronzo, MD is an expert in the field of Endocrinology. He attended Harvard Medical School. Harvard Medical School is a one of the best medicals schools. Harvard Medical School has a rank of 1 in research and a 12 in primary care Ralph Defronzo is a published doctor and has 101 publications published. The lastest was: 'Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor.'
Publications
- Revitalization of Pioglitazone: The Optimal Agent to be Combined with an SGLT2 Inhibitor.
- Empagliflozin and linagliptin combination therapy for treatment of patients with type 2 diabetes mellitus.
- The EMPA-REG study: What has it told us? A diabetologist's perspective.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The Primary Glucose-Lowering Effect of Metformin Resides in the Gut, Not the Circulation. Results From Short-term Pharmacokinetic and 12-Week Dose-Ranging Studies.
- Peripheral insulin resistance and impaired insulin signaling contribute to abnormal glucose metabolism in preterm baboons.
- Dapagliflozin Lowers Plasma Glucose Concentration and Improves Beta Cell Function.
- Chronic continuous exenatide infusion does not cause pancreatic inflammation and ductal hyperplasia in non-human primates.
- A Novel Insulin Resistance Index to Monitor Changes in Insulin Sensitivity and Glucose Tolerance: the ACT NOW Study.
- The effect of muraglitazar on adiponectin signalling, mitochondrial function and fat oxidation genes in human skeletal muscle in vivo.
- Adjusting Glucose-Stimulated Insulin Secretion for Adipose Insulin Resistance: An Index of β-Cell Function in Obese Adults.
- Metabolites as novel biomarkers for childhood obesity-related traits in Mexican-American children.
- Initial Combination Therapy with Metformin/Pioglitazone/Exenatide is More Effective Than Sequential Add-On Therapy in Subjects with New Onset Diabetes. Results from th...
- What are the pharmacotherapy options for treating prediabetes?
- The Disposition Index Does Not Reflect Beta Cell Function in IGT Subjects Treated with Pioglitazone.
- APPL1 Potentiates Insulin Sensitivity by Facilitating the Binding of IRS1/2 to the Insulin Receptor.
- Strong Association Between Insulin-Mediated Glucose Uptake and the 2-Hour, Not the Fasting Plasma Glucose Concentration in the Normal Glucose Tolerance Range.
- Baseline Adiponectin Levels Do Not Influence the Response to Pioglitazone in ACT NOW.
- Lowering Plasma Glucose Concentration by Inhibiting Renal Sodium-Glucose Co-Transport.
- Successful β cells islet regeneration in streptozotocin-induced diabetic baboons using ultrasound-targeted microbubble gene therapy with cyclinD2/CDK4/GLP1.
- Sequence variants in SLC16A11 are a common risk factor for type 2 diabetes in Mexico.
- Chronic Reduction of Plasma FFA Improves Mitochondrial Function and Whole Body Insulin Sensitivity in Obese and Type 2 Diabetic Individuals.
- Morbid Obesity Resulting from Inactivation of the Ciliary Protein CEP19 in Humans and Mice.
- Combined acute hyperglycemic and hyperinsulinemic clamp induced profibrotic and proinflammatory responses in the kidney.
- Novel Hypothesis to Explain Why SGLT2 Inhibitors Inhibit Only 30-50% of Filtered Glucose Load in Humans.
- Prediction of Diabetes Based on Baseline Metabolic Characteristics in Individuals at High Risk.
- Genetic Disruption of SOD1 Gene Causes Glucose Intolerance and Impairs β-cell Function.
- Genetic epidemiology of cardiometabolic risk factors and their clustering patterns in Mexican American children and adolescents: the SAFARI Study.
- Dapagliflozin for the treatment of type 2 diabetes.
- Prevention of Diabetes with Pioglitazone in Act Now: Physiologic Correlates.
- Characterization of Renal Glucose Reabsorption in Response to Dapagliflozin in Healthy Subjects and Subjects With Type 2 Diabetes.
- Pioglitazone improves glucose metabolism and modulates skeletal muscle TIMP-3-TACE dyad in type 2 diabetes mellitus: a randomised, double-blind, placebo-controlled, me...
- Localization of a major susceptibility locus influencing preterm birth on chromosome 18q in Mexican Americans.
- Pleiotropic effects of thiazolidinediones: implications for the treatment of patients with type 2 diabetes mellitus.
- Mechanisms of Glucose Lowering of Dipeptidyl Peptidase-4 Inhibitor Sitagliptin When Used Alone or With Metformin in Type 2 Diabetes: A double-tracer study.
- Effect of Pioglitazone on Body Composition and Bone Density in Subjects with Prediabetes in the ACT NOW Trial.
- Effect of a Sustained Reduction in Plasma Free Fatty Acid Concentration onInsulin Signaling and Inflammation in Skeletal Muscle from Human Subjects.
- Pioglitazone slows progression of atherosclerosis in prediabetes independent of changes in cardiovascular risk factors.
- Impact of obesity severity and duration on pancreatic β- and α-cell dynamics in normoglycemic non-human primates.
- Fat-Specific DsbA-L Overexpression Promotes Adiponectin Multimerization and Protects Mice From Diet-Induced Obesity and Insulin Resistance.
- Insulin Versus GLP-1 Analogues in Poorly Controlled Type 2 Diabetic Subjects on Oral Therapy A Meta Analysis.
- Efficacy and Safety of SGLT2 Inhibitors in the Treatment of Type 2 Diabetes Mellitus.
- Successful treatment of prediabetes in clinical practice: targeting insulin resistance and β-cell dysfunction.
- Estimation of prehepatic insulin secretion: comparison between standardized C-peptide and insulin kinetic models.
- APPL1 Mediates Adiponectin-Induced LKB1 Cytosolic Localization Through the PP2A-PKC{zeta} Signaling Pathway.
- Assessment and treatment of cardiovascular risk in prediabetes: impaired glucose tolerance and impaired fasting glucose.
- Two-Step Approach for the Prediction of Future Type 2 Diabetes Risk.
- Preservation of {beta}-Cell Function: The Key to Diabetes Prevention.
- Reduction in Reactive Oxygen Species Production by Mitochondria From Elderly Subjects With Normal and Impaired Glucose Tolerance.
- Role of Glycated Hemoglobin in the Prediction of Future Risk of T2DM.
- Role of Sodium-Glucose Cotransporter 2 (SGLT 2) Inhibitors in the Treatment of Type 2 Diabetes.
- Impaired early- but not late-phase insulin secretion in subjects with impaired fasting glucose.
- Type 2 diabetes can be prevented with early pharmacological intervention.
- Bromocriptine: a sympatholytic, d2-dopamine agonist for the treatment of type 2 diabetes.
- The relationship between {beta}-cell function and glycated hemoglobin: results from the veterans administration genetic epidemiology study.
- Mechanism and effects of glucose absorption during an oral glucose tolerance test among females and males.
- Coordinated defects in hepatic long chain Fatty Acid metabolism and triglyceride accumulation contribute to insulin resistance in non-human primates.
- Does Reduced IGF-1R Signaling in Igf1r Mice Alter Aging?
- NF-?B activity in muscle from obese and type 2 diabetic subjects under basal and exercise-stimulated conditions.
- Reduced time points to calculate the composite index.
- Effects of exenatide plus rosiglitazone on beta-cell function and insulin sensitivity in subjects with type 2 diabetes on metformin.
- The ontogeny of insulin signaling in the preterm baboon model.
- Effects of pioglitazone on intramyocellular fat metabolism in patients with type 2 diabetes mellitus.
- Current issues in the treatment of type 2 diabetes. Overview of newer agents: where treatment is going.
- Current issues in the treatment of type 2 diabetes. Introduction.
- Minimal contribution of fasting hyperglycemia to the incidence of type 2 diabetes in subjects with normal 2-h plasma glucose.
- Effect of short-term free Fatty acids elevation on mitochondrial function in skeletal muscle of healthy individuals.
- Pathogenesis of insulin resistance in skeletal muscle.
- Plasma glucose concentration and prediction of future risk of type 2 diabetes.
- Skeletal muscle insulin resistance is the primary defect in type 2 diabetes.
- Pancreatic islet amyloidosis, beta-cell apoptosis, and alpha-cell proliferation are determinants of islet remodeling in type-2 diabetic baboons.
- Circulating fibroblast growth factor-21 is elevated in impaired glucose tolerance and type 2 diabetes and correlates with muscle and hepatic insulin resistance.
- Oral disposition index predicts the development of future diabetes above and beyond fasting and 2-h glucose levels: response to Utzschneider et al.
- Pathophysiology of prediabetes.
- Whole body overexpression of PGC-1alpha has opposite effects on hepatic and muscle insulin sensitivity.
- Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus.
- Retinol-binding protein 4 is associated with impaired glucose tolerance but not with whole body or hepatic insulin resistance in Mexican Americans.
- Fasting versus postload plasma glucose concentration and the risk for future type 2 diabetes: results from the Botnia Study.
- Plasma ceramides are elevated in obese subjects with type 2 diabetes and correlate with the severity of insulin resistance.
- Genome-wide linkage scan for genes influencing plasma triglyceride levels in the Veterans Administration Genetic Epidemiology Study.
- Elevated concentrations of liver enzymes and ferritin identify a new phenotype of insulin resistance: effect of weight loss after gastric banding.
- Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes and inadequate glycemic control: a randomized, double-blind, pl...
- Efficacy and safety of Technosphere inhaled insulin compared with Technosphere powder placebo in insulin-naive type 2 diabetes suboptimally controlled with oral agents.
- Elevated toll-like receptor 4 expression and signaling in muscle from insulin-resistant subjects.
- Deleterious action of FA metabolites on ATP synthesis: possible link between lipotoxicity, mitochondrial dysfunction, and insulin resistance.
- Inhibition of renal glucose reabsorption: a novel strategy for achieving glucose control in type 2 diabetes mellitus.
- The relationship between fasting hyperglycemia and insulin secretion in subjects with normal or impaired glucose tolerance.
- One-hour plasma glucose concentration and the metabolic syndrome identify subjects at high risk for future type 2 diabetes.
- Association of genetic variation in ENPP1 with obesity-related phenotypes.
- Mitochondrial dysfunction, insulin resistance, and type 2 diabetes mellitus.
- Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes.
- Effect of acute physiological hyperinsulinemia on gene expression in human skeletal muscle in vivo.
- Physiological and molecular determinants of insulin action in the baboon.
- Decreased non-insulin-dependent glucose clearance contributes to the rise in fasting plasma glucose in the nondiabetic range.
- Insulin reduces plasma arginase activity in type 2 diabetic patients.
- Peripheral disruption of the Grb10 gene enhances insulin signaling and sensitivity in vivo.
- Relationship between hepatic/visceral fat and hepatic insulin resistance in nondiabetic and type 2 diabetic subjects.
- What is the best predictor of future type 2 diabetes?
- Fasting hyperglycemia impairs glucose- but not insulin-mediated suppression of glucagon secretion.
- Association of neuropeptide Y receptor Y5 polymorphisms with dyslipidemia in Mexican Americans.
Schools
Harvard Medical School
Johns Hopkins Hospital
Nih Baltimore City Hospital
University Of Pennsylvania
Conditions Treated
- Gout
Doctors Specialties
- Nephrology
- Endocrinology
Accepted Insurances
Education
-
University of Pennsylvania Health System -
Johns Hopkins University -
Harvard Medical School
Hospital
-
University Health System -
South Texas Veterans Health Care System
Helpful Reviews
Similar Doctors
|
|
Dr. Jerome S. Fischer, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rashid Sharaf, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Milagros A. Martinez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeannie A. Baquero, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Amna A. Salhin, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicolas Musi, MD
This Doctor is OpenDoctor Recommended.
|